GC patients with MUC16 mutations were significantly associated with a higher TMB (P < 0.001) and better survival outcomes (HR = 1.792, P = 0.002) than patients without MUC16 mutations (Figures 1B,C). This evidence concerns the gene MUC16 and gastric cancer.